Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161884 | 0.97 | TSHR (0.44) | TSHR | |
| SCHEMBL16309022 | 0.91 | TSHR (0.44) | TSHR | |
| SCHEMBL12687548 | 0.84 | — | — | |
| SCHEMBL8717863 | 0.83 | ESR1 (0.35) | TSHRGRM5 | |
| SCHEMBL26721949 | 0.80 | ESR1 (0.36) | TSHR | |
| SCHEMBL23603998 | 0.74 | TSHR (0.33) | TSHR | |
| SCHEMBL26721931 | 0.74 | — | — | |
| SCHEMBL2238894 | 0.73 | ALDH1A1 (0.32) | — | |
| SCHEMBL458413 | 0.73 | ALDH1A1 (0.32) | — | |
| SCHEMBL22116424 | 0.73 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007004226-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF MALE ERECTILE DYSFUNCTION (ED) | DARLEY PHARMACUETICALS LTD. (IL) | 2007-01-11 | — | — | WO | claimed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3983383-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3845545-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| EP-2461683-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2364088-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010051030-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-7288613-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060149011-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | NESVADBA PETER | 2006-07-06 | — | — | US | disclosed |
| EP-1343827-A1 | N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002048205-A1 | N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | TSHR 521/4885GRM5 411/4885 |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | TSHR 452/4885GRM5 1484/4885 |
| US-20060149011-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | ALKBH2, ALKBH3, ALKBH5 | TSHR 4785/4885GRM5 1657/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | TSHR 4117/4885GRM5 1469/4885 |
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | TSHR 638/4885GRM5 438/4885 |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TSHR 4477/4885GRM5 1018/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | TSHR 4117/4885GRM5 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.